Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of A
BALA CYNWYD, Pa. , Dec. 23, 2025 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky
What's Going On With BioMarin Stock On Tuesday?
01:05pm, Tuesday, 23'rd Dec 2025
On Friday, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) agreed to acquire Amicus Therapeutics, Inc. (NASDAQ: FOLD) for a total equity value of about $4.8 billion.
BioMarin: Amicus Buyout Sparks My Enthusiasm
03:15pm, Monday, 22'nd Dec 2025
BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market. It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example,
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B
12:52pm, Monday, 22'nd Dec 2025
BMRN agrees to acquire FOLD for $4.8B, adding two growing rare disease drugs and a late-stage pipeline asset to its portfolio.
Top large-cap gainers for Dec. 15-19 were led by Rivian, Moderna, and BioMarin, rising on product/software updates, vaccine funding news, and a major acquisition deal, with Rocket Lab, Affirm, and cru
BioMarin Pharmaceutical Inc. $BMRN Stake Cut by Assenagon Asset Management S.A.
03:34am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. cut its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 66.9% in the third quarter, according to its most recent filing with the Securities and Exc
Market Today: Oracle-TikTok JV, Tesla Pay Reinstated, Nike Sinks
05:35pm, Friday, 19'th Dec 2025
Guru Stock PicksVanguard Health Care Fund has made the following transactions:Reduce in ARGX by 14.38%Sold out in PACSAdd in CLDX by 3.64%New position in PTGXCI
Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play
12:41pm, Friday, 19'th Dec 2025
BioMarin Pharmaceutical Inc. (BMRN) has agreed to acquire Amicus Therapeutics Inc. (FOLD) in a transaction valued at about $4.8 billion, a move that could stren
BioMarin Acquires Amicus Therapeutics in $4.8 Billion Deal
12:14pm, Friday, 19'th Dec 2025
BioMarin (BMRN) is acquiring Amicus Therapeutics (FOLD) for $14.50 per share in an all-cash deal valued at approximately $4.8 billion. This acquisition, expecte
BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript
11:27am, Friday, 19'th Dec 2025
BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript
BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.
10:55am, Friday, 19'th Dec 2025
It's the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst
10:36am, Friday, 19'th Dec 2025
CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperform and highlight 2026 clinical milestones.
BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal
09:03am, Friday, 19'th Dec 2025
BioMarin said Friday it will acquire Amicus Therapeutics for $4.8 billion in a deal that adds two rare disease drugs to its portfolio.
